𝔖 Bobbio Scriptorium
✦   LIBER   ✦

3,3′-diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model

✍ Scribed by Han Jin Cho; So Young Park; Eun Ji Kim; Jin-Kyung Kim; Jung Han Yoon Park

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
773 KB
Volume
50
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of the nuclear matrix p
Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer
✍ Eddy S. Leman; Julie A. Arlotti; Rajiv Dhir; Norman Greenberg; Robert H. Getzenb 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 637 KB

The nuclear matrix (NM) contains a number of proteins that have been found to be associated with transformation. We have previously identified changes in the NM associated with prostate cancer. In this study, we examine the molecular changes that are associated with prostate cancer development in tr

Inactivation of uPA and its receptor uPA
Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration
✍ Aamir Ahmad; Dejuan Kong; Sanila H. Sarkar; Zhiwei Wang; Sanjeev Banerjee; Fazlu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 514 KB

## Abstract 3,3′‐Diindolylmethane (DIM) has been studied for its putative anti‐cancer properties, especially against prostate cancer; however, its exact mechanism of action remains unclear. We recently provided preliminary data suggesting down‐regulation of uPA during B‐DIM (a clinically active DIM

Inhibition of CXCR4/CXCL12 signaling axi
Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model
✍ Muthu K. Shanmugam; Kanjoormana A. Manu; Tina H. Ong; Lalitha Ramachandran; Rohi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 631 KB

## Abstract Increasing evidences indicate that CXCR4/CXCL12 signaling pathway plays a pivotal role in the process of distant site metastasis that accounts for more than 90% of prostate cancer related deaths in patients. Thus, novel drugs that can downregulate CXCR4/CXCL12 axis have a great potentia

Orthotopic treatment model of prostate c
Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy
✍ Kenneth D. Somers; Roy R. Brown; Daniel A. Holterman; Nazita Yousefieh; William 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 376 KB 👁 1 views

## Abstract We established an orthotopic treatment model of prostate cancer to generate reproducible primary and metastatic carcinoma in immunocompetent C57BL/6 mice. Using an __in vivo__ selection scheme of intraprostatic implantation of TRAMP‐C1 cells, primary prostate tumors were cultured and re

Nuclear matrix localization of high mobi
Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer
✍ Eddy S. Leman; Michael C. Madigan; Gisela Brünagel; Natsuki Takaha; Donald S. Co 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

## Abstract Nuclear shape and the underlying nuclear structure, the nuclear matrix in cancer cells. Since the NM composition is considered to maintain nuclear shape and architecture, nuclear matrix proteins (NMPs) may be involved in transformation. Our laboratory has recently characterized a subset

Gene-directed enzyme prodrug therapy for
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease
✍ Rosetta Martiniello-Wilks; Allison Dane; Dale J. Voeks; Geetha Jeyakumar; Elin M 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB 👁 1 views

## Abstract ## Background Gene‐directed enzyme prodrug therapy (GDEPT) based on the __E. coli__ enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludar